ASN: Bardoxolone methyl no benefit in T2DM, stage 4 CKD

ASN: bardoxolone methyl no benefit in T2DM, stage 4 CKD

(HealthDay)—Bardoxolone methyl does not reduce the risk of end-stage renal disease (ESRD) or cardiovascular death in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, according to a study published online Nov. 9 in the New England Journal of Medicine. This research was published to coincide with the annual meeting of the American Society of Nephrology (Kidney Week), held from Nov. 5 to 10 in Atlanta.

Dick de Zeeuw, M.D., Ph.D., from the University of Groningen in the Netherlands, and colleagues randomized 2,185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease to receive bardoxolone methyl or placebo. Participants were followed for the primary composite outcome of ESRD or .

On the recommendation of the independent data and safety monitoring committee, the trial was terminated early, with a median follow-up of nine months. The researchers found that the primary composite outcome occurred in 6 percent of the 1,088 patients assigned to bardoxolone methyl and 6 percent of the 1,097 assigned to placebo. Significantly more patients in the bardoxolone methyl group were hospitalized for or died from heart failure compared with the (96 versus 55 patients; hazard ratio, 1.83).

"Among patients with type 2 diabetes mellitus and stage 4 , bardoxolone methyl did not reduce the risk of ESRD or death from cardiovascular causes," the authors write.

The study was funded by Reata Pharmaceuticals, a manufacturer of bardoxolone methyl.

More information: Abstract
Full Text
Editorial
More Information

add to favorites email to friend print save as pdf

Related Stories

Median follow-up results from the ALTITUDE study

Aug 27, 2012

Preliminary results from the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) do not support administration of aliskiren on top of standard therapy with renin-angiotensin-aldosterone system (RAAS) ...

Recommended for you

Screening for diabetes at dental visits using oral blood

Feb 26, 2015

It is estimated that 8.1 million of the 29.1 million Americans living with diabetes are undiagnosed and many who have diabetes have poor glycemic control. Given that each year many Americans visit a dental provider but not ...

CBT, sertraline insufficient in diabetes and depression

Feb 26, 2015

(HealthDay)—For patients with diabetes and depression, improvements in depression are seen with cognitive behavioral therapy (CBT) or sertraline, with a significant advantage for sertraline, but glycemic ...

Early signs in young children predict type 1 diabetes

Feb 26, 2015

New research shows that it is possible to predict the development of type 1 diabetes. By measuring the presence of autoantibodies in the blood, it is possible to detect whether the immune system has begun to break down the ...

Daily menu plan reduces blood sugar significantly

Feb 25, 2015

A large group of people with diabetes who followed a menu plan created by University of Alberta nutrition researchers for just three months significantly reduced their blood sugar levels.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.